Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody
Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody - Image 2
Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody - Image 3
Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody - Image 4

Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody

Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody — recombinant protein.

SKU: BCREC-000488MA Category:
Online Inquiry →

Product Specifications

Uniprot No.P35579
Target NamesMYH9
Species ReactivityMouse
ImmunogenRecombinant Human MYH9 protein
Immunogen SpeciesHomo sapiens (Human)
ConjugateNon-conjugated
IsotypeMouse IgG2b
ClonalityMonoclonal
ApplicationsELISA, WB, FC
BufferPBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
StorageUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Function

(Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B.

Biological Context

Subcellular Location: Cell membrane
Tissue Specificity: In the kidney, expressed in the glomeruli. Also expressed in leukocytes
Disease Association: Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss (MATINS) : An autosomal dominant disorder characterized by thrombocytopenia, giant platelets and Dohle body-like inclusions in peripheral blood leukocytes with variable ultrastructural appearance. Some affected individuals lack leukocyte inclusion bodies on classic staining of peripheral blood smears. Alport syndrome-like features of nephritis, hearing loss, and eye abnormalities are present in some patients. [The disease is caused by variants affecting the gene represented in this entry] | Deafness, autosomal dominant, 17 (DFNA17) : A form of deafness characterized by progressive high frequency hearing impairment and cochleosaccular degeneration. [The disease is caused by variants affecting the gene represented in this entry] | [Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures] | [Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD)]

Product Specifications

Mouse anti-Human sapiens (Human) MYH9 Monoclonal Antibody is a recombinant protein. Suitable for ELISA and Western Blot applications.

Applications: ELISA, WB, FC

Biological Activity: Not implied unless activity data are explicitly listed on this product page, the datasheet, or the CoA.

Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Shipping & Lead Time: Availability, shipping conditions, and estimated lead time are confirmed in the formal quotation or order confirmation based on the product format, destination, and order requirements.

Related products

Protein Biology

Function

(Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B

Subcellular Location

Cell membrane

Disease Association

Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss (MATINS) : An autosomal dominant disorder characterized by thrombocytopenia, giant platelets and Dohle body-like inclusions in peripheral blood leukocytes with variable ultrastructural appearance. Some affected individuals lack leukocyte inclusion bodies on classic staining of peripheral blood smears. Alport syndrome-like features of nephritis, hearing loss, and eye abnormalities are present in some patients. [The disease is caused by variants affecting the gene represented in this entry] | Deafness, autosomal dominant, 17 (DFNA17) : A form of deafness characterized by progressive high frequency hearing impairment and cochleosaccular degeneration. [The disease is caused by variants affecting the gene represented in this entry] | [Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures] | [Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD)]

Tissue Specificity

In the kidney, expressed in the glomeruli. Also expressed in leukocytes

Subunit

(Microbial infection) Interacts with herpes simplex virus 1/HHV-1 envelope glycoprotein B

Gene: MYH9  |  Organism: Homo sapiens  |  Synonyms: Cellular myosin heavy chain, type A; Myosin heavy chain 9; Myosin heavy chain, non-muscle IIa; Non-muscle myosin heavy chain A; Non-muscle myosin heavy chain IIa
Key Publications

Explore closely related product collections, technology platforms, and custom production resources.

Frequently Asked Questions

How do I order or inquire about this product?

Submit the Online Inquiry form with your required quantity and specifications, or email sales@biocrestsci.com. Available sizes, pricing, stock status, documentation, and estimated lead time are confirmed in the formal quotation.

What is the shipping and delivery time?

Availability, dispatch timing, shipping conditions, and delivery estimates depend on the product format, destination, and order requirements. These details are confirmed in the formal quotation or order confirmation.

How should this product be stored?

Follow the storage and handling instructions in the product-specific datasheet and Certificate of Analysis (CoA). Requirements may vary by product form and formulation; contact BioCrest Sci if product-specific guidance is needed.

What quality controls are performed on your products?

Quality-control data such as identity, purity, endotoxin level, or biological activity are provided only when specified on this product page, the datasheet, or Certificate of Analysis (CoA). Biological activity is not implied unless explicitly stated.

Shopping Cart
Scroll to Top